The Company Signs Supply Agreement with Nectar Health Sciences Laboratory Division Inc. to provide naturally derived psilocybin for research and development of therapeutic products VANCOUVER, BC, Nov. 22, 2021 /CNW/ – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP)(the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for the…


Previous articleNuminus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021
Next articlePT274 – Juan Pablo Cappello – Nue Life: Using Digital Phenotyping to Personalize Healthcare